Penumbra, Inc.

PEN Healthcare Medical Devices

Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.

Revenue
+15.6%
EPS
−8.29%
Free cash flow
−37.2%
Total debt
−10.3%

Quarter to September 2026, against a year earlier

319.20 1.91 −0.59%
Market cap
$12.7B
P/E
80.3×
Fwd P/E
68.7×
Dividend yield
—
F-score
8/9
Altman Z
20.17
Beneish M
−2.48
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

68.03 74.97 77.20 79.72
P/S ratio
8.62 8.87 8.26 8.04
P/FCF ratio
69.17 60.62 57.55 62.62
P/Operating CF
139.91 148.29 269.64 302.19
P/B ratio
8.48 8.75 8.12 7.92
EV/Sales
8.25 8.46 7.83 7.62
EV/EBITDA
56.00 60.25 57.64 56.79
EV/FCF
66.17 57.83 54.59 59.36
Current Ratio
6.64 6.02 5.75 5.89
Net Debt/EBITDA
(8.23) (13.91) (13.70) (11.65)
Debt/Equity
0.01 0.01 0.01 0.01
Earnings Yield
1.47% 1.33% 1.30% 1.25%
Free Cash Flow Yield
1.45% 1.65% 1.74% 1.60%
Free Cash Flow per Share
1.75 1.87 0.83 0.67
Book value per Share
36.68 37.53 38.90 40.19
Free Cash Flow
68.05 73.30 32.54 26.40
EV/EBIT
61.17 65.74 62.92 62.82
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026